Cellectis(CLLS) Newsfilter·2024-05-27 20:30Core Viewpoint - Cellectis, a clinical-stage biotechnology company, is set to report its financial results for Q1 2024 on May 28, 2024, followed by an investor conference call on May 29, 2024, to discuss the results and business updates [1][2]. Company Overview - Cellectis specializes in developing life-saving cell and gene therapies using its gene-editing platform, focusing on CAR-T immunotherapies for oncology and therapeutic gene editing in hemopoietic stem cells [3]. - The company employs an allogeneic approach for CAR-T therapies, aiming to provide off-the-shelf, ready-to-use gene-edited CAR T-cells for cancer treatment [3]. - Cellectis has over 24 years of experience in gene editing and utilizes technologies such as TALEN® and PulseAgile to address unmet medical needs [3]. - The company is headquartered in Paris, France, with additional locations in New York and Raleigh, and is listed on both Nasdaq (ticker: CLLS) and Euronext Growth (ticker: ALCLS) [3].